## DEBIO 1143 MODE OF ACTION A BROAD CHEMO-RADIO AND IMMUNO-THERAPY SENSITIZER



When a tumor cell is damaged by cytotoxic treatments such as chemo-radiotherapy (CRT), programmed cell death – or apoptosis – can be triggered via the activation of caspases which are negatively regulated by IAPs (Inhibitor of Apoptosis Proteins).<sup>1,2</sup> Sometumor cells escape from this controlled pathway and thus survive and proliferate.<sup>2,3</sup>



## ENHANCED EFFECT OF CRT ON CANCER CELLS WITH THE ADDITION OF DEBIO 1143



Debio 1143 is a potential **first-in-class oral antagonist of IAPs**, acting as a chemo-radio and immuno-therapy sensitizer to enhance treatment efficacy.<sup>4-6</sup> By inhibiting IAPs, **combined with CRT**, Debio 1143 enhances the killing of cancer cells by CRT, facilitating the destruction of the tumor.<sup>6,7</sup> Moreover, in pre-clinical studies, Debio 1143 directly enhanced T lymphocyte activation and improved the effects of immune checkpoint inhibitors (ICIs), making it an attractive investigational approach **in combination with immunotherapy**.<sup>56,89</sup>



## References:

- 1. Fernald K et al. Trends Cell Biol. 2013;23(12):620-633.
- 2. Finlay D et al. F1000Research. 2017;6:587.
- 3. Rathore R et al. Apoptosis. 2017;22:898-919.
- Matzinger O et al. Oncology. 2015;116(3):495-503.
  Tao Z et al. Clin Cancer Res. 2019;25(3): 1113-1124.
- Attinger A et al. (poster) AACR 2018.
- Bourhis J et al. (poster) ESMO 2019.
  Dougan SK et al. Immunotherapy. 2018;10(9):787–796.
- Bougari Skiet al. Infinitionerapy. 2018;10(9):767–796
  Rotschild U et al. Swiss Med Wkly. 2018;148:w14625.